Suppr超能文献

相似文献

2
MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Cancer Biol Ther. 2010 Jun 1;9(11):936-44. doi: 10.4161/cbt.9.11.11882. Epub 2010 Jun 27.
4
5
Nutlin's two roads toward apoptosis.
Cancer Biol Ther. 2010 Sep 15;10(6):579-81. doi: 10.4161/cbt.10.6.13127. Epub 2010 Sep 24.
7
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Oncogene. 2008 Feb 7;27(7):997-1003. doi: 10.1038/sj.onc.1210707. Epub 2007 Aug 13.

引用本文的文献

1
Regulatory role of E3 ubiquitin ligases in multiple myeloma: from molecular mechanisms to therapeutic strategies.
Front Cell Dev Biol. 2025 Jul 30;13:1620097. doi: 10.3389/fcell.2025.1620097. eCollection 2025.
2
Harnessing p53 for targeted cancer therapy: new advances and future directions.
Transcription. 2025 Feb;16(1):3-46. doi: 10.1080/21541264.2025.2452711. Epub 2025 Mar 3.
4
MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression.
Genes (Basel). 2022 Dec 29;14(1):100. doi: 10.3390/genes14010100.
5
Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma.
Cancers (Basel). 2022 Mar 21;14(6):1592. doi: 10.3390/cancers14061592.
6
Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
Cell Mol Biol Lett. 2021 Dec 15;26(1):53. doi: 10.1186/s11658-021-00293-6.
7
Pathway-Directed Therapy in Multiple Myeloma.
Cancers (Basel). 2021 Apr 1;13(7):1668. doi: 10.3390/cancers13071668.
8
Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.
Cells. 2021 Feb 5;10(2):336. doi: 10.3390/cells10020336.
9
Rationally Designed Polypharmacology: α-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1 and HDM2.
ChemMedChem. 2020 Sep 16;15(18):1691-1698. doi: 10.1002/cmdc.202000278. Epub 2020 Jun 25.
10
Prognosis, Biology, and Targeting of Dysregulation in Multiple Myeloma.
Cells. 2020 Jan 24;9(2):287. doi: 10.3390/cells9020287.

本文引用的文献

1
MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Cancer Biol Ther. 2010 Jun 1;9(11):936-44. doi: 10.4161/cbt.9.11.11882. Epub 2010 Jun 27.
2
Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
Int J Cancer. 2010 May 15;126(10):2268-81. doi: 10.1002/ijc.25102.
3
Pharmacological activation of the p53 pathway in haematological malignancies.
J Clin Pathol. 2010 Mar;63(3):204-9. doi: 10.1136/jcp.2009.070961. Epub 2009 Dec 2.
4
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Clin Cancer Res. 2009 Dec 1;15(23):7153-60. doi: 10.1158/1078-0432.CCR-09-1071. Epub 2009 Nov 24.
6
7
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Annu Rev Pharmacol Toxicol. 2009;49:223-41. doi: 10.1146/annurev.pharmtox.48.113006.094723.
8
Targeting the MDM2-p53 interaction for cancer therapy.
Clin Cancer Res. 2008 Sep 1;14(17):5318-24. doi: 10.1158/1078-0432.CCR-07-5136.
9
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.
Blood. 2008 Nov 1;112(9):3827-34. doi: 10.1182/blood-2008-05-156380. Epub 2008 Aug 5.
10
lumi: a pipeline for processing Illumina microarray.
Bioinformatics. 2008 Jul 1;24(13):1547-8. doi: 10.1093/bioinformatics/btn224. Epub 2008 May 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验